Tue, Sep 23, 2014, 1:16 PM EDT - U.S. Markets close in 2 hrs 44 mins

Recent

% | $
Quotes you view appear here for quick access.

Isis Pharmaceuticals, Inc. Message Board

thehorse2002 12 posts  |  Last Activity: 3 hours ago Member since: Jan 16, 2003
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • thehorse2002 thehorse2002 3 hours ago Flag

    You are correct, it was put in place if the event spiked the stock. It didn't and so no sale of stock at these levels, obviously.

    Sentiment: Buy

  • Merck KGaA is talking up deals again, pointing to its healthy cash reserves and saying it can well afford a blockbuster buyout to bolster its pipeline. But that's been the story for nearly a year, so what's the German giant waiting on?

    On the company's second-quarter earnings call, CEO Karl-Ludwig Kley told reporters that Merck KGaA is looking at some "interesting" targets but said there's no rush. "We can but we don't have to pursue acquisitions," he said, according to

    Sentiment: Strong Buy

  • Reply to

    The Firm & it's Shareholders deserve better!

    by thehorse2002 Aug 1, 2014 12:26 PM
    thehorse2002 thehorse2002 Aug 1, 2014 4:56 PM Flag

    LOL, yeah right...

    Sentiment: Strong Buy

  • The Illustrious Broker-dealer Moe, Larry & Curly, Inc. are doing what they do best today;
    Confirming that Threshold has the absolute worst Market Maker of any biotech stock I've seen in more years than I care to mention. I realize that Barry is a scientist and not a Wall street maven but he can always ask the advice of some respected party, right? The Market making is pathetic and low rent, the firm and it's shareholders deserve better.

    Sentiment: Strong Buy

  • One day in the not too distant future the headline will include Celldex, no doubt at all!
    AstraZeneca ($AZN) has partnered up with Princeton, NJ-based Advaxis on a program that pairs the pharma giant's closely watched immuno-oncology drug MEDI4736 with the biotech's therapeutic cancer vaccine for HPV-related cancers.

    Sentiment: Strong Buy

  • Reply to

    How I destroyed Celldex by A. Marucci.

    by weightbayou Jul 16, 2014 3:17 PM
    thehorse2002 thehorse2002 Jul 17, 2014 10:28 AM Flag

    Painful to watch it trade poorly? Yes, worrying? Absolutely not, it's being played around with, obviously.
    The science is why we own it. The share price will recover and reach new highs. In the meantime, while it gets jerked around by the shorts, my advice is; don't watch every tick, it will only make you nervous.
    Have faith, we will be richly rewarded you in time.

    Sentiment: Strong Buy

  • thehorse2002 thehorse2002 Jul 16, 2014 3:40 PM Flag

    First of all, it's a sell of 50k, then a buy, a simple cross @1/2 penny. Secondly the volume is pretty anemic, as usual. Last but not least, the Marketing Making on THLD is putrid, it's being done by that renowned firm;
    Moe Larry & Curly, Inc.
    Having said this, it's a strong buy regardless of how it trades.

    Sentiment: Strong Buy

  • Bristol-Myers Squibb ($BMY) plans to submit its closely watched cancer candidate nivolumab for FDA approval to treat melanoma next quarter, outpacing analysts' expectations and setting the stage for a duel with Merck's ($MRK) rival drug.

    The drug, nivolumab, is a cancer treatment designed to galvanize the immune system against a wide range of tumor cells by blocking a pathway called PD-1. Bristol-Myers' planned application would cover melanoma patients previously treated with the company's own Yervoy, and, if approved, the drug would trade under the name Opdivo.

    The filing is well ahead of Wall Street's expectation of a mid-2015 submission, according to ISI Group analyst Mark Schoenebaum, and the accelerated move puts Bristol-Myers about 8 months behind Merck, whose PD-1-blocking pembrolizumab (MK-3475) is expected to get final word on its melanoma application by Oct. 28.

    Meanwhile, Bristol-Myers is working through a rolling FDA submission for nivolumab in non-small cell lung cancer, expecting to complete the filing by year's end. And the company is bankrolling a sweeping clinical program for the promising drug, studying its effects on renal cell carcinoma, head and neck cancer, glioblastoma, and non-Hodgkin lymphoma, among other cancers.

    At stake is the largest share of a PD-1 market projected to peak as high as $35 billion a year, and Bristol-Myers is racing with Merck, AstraZeneca ($AZN), Roche ($RHHBY) and others to string together FDA approvals and capitalize on stellar data for the whole class.

    And while Merck is almost certain to hit the U.S. market first, nivolumab became the first PD-1 inhibitor approved anywhere in the world when it picked up a Japanese nod earlier this week.

    Sentiment: Strong Buy

  • The anti-PD-1 immuno-oncology drug star nivolumab has won the race to the world's first regulatory checkered flag for an approval. Ono Pharmaceutical, which picked up the Japanese rights to the drug in a collaboration deal with Medarex back in 2005, says regulators in the Asian country approved nivolumab for sale as a treatment for unresectable melanoma.

    Sentiment: Strong Buy

  • Very nice deal for Mersana, clearly Merck KGaA is constantly on the hunt for new product.

    Mersana Therapeutics has inked another antibody-drug conjugate development pact, this time with the R&D team at Merck KGaA in Germany.

    The Cambridge, MA-based biotech reported this morning that Merck KGaA will offer up some antibodies for use in ADCs, in which an antibody homes in on cancer cells to deliver highly toxic and targeted drugs. There were no numbers in the statement, but a spokesperson for the company says that the package includes $792 million in upfront and potential milestone payments. There was no breakout in the upfront, though discovery deals like this are typically heavily back-ended with biobucks.

    Sentiment: Strong Buy

  • Reply to

    VNDA PREVAILS

    by clarkjohn18 Jun 23, 2014 2:29 PM
    thehorse2002 thehorse2002 Jun 23, 2014 2:56 PM Flag

    I've been in and out since $1 before the Fanapt approval, I understand your plan.
    Good luck.

    Sentiment: Strong Buy

  • Reply to

    VNDA PREVAILS

    by clarkjohn18 Jun 23, 2014 2:29 PM
    thehorse2002 thehorse2002 Jun 23, 2014 2:50 PM Flag

    Bad move to sell here. Who really cares if it loses 50 cents or a buck, it's obvioulsy going much higher. Buy it back soon and hold it.

    Sentiment: Strong Buy

ISIS
40.3508-0.3592(-0.88%)1:16 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.